These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 22834474)

  • 21. Lubiprostone: in constipation-predominant irritable bowel syndrome.
    Carter NJ; Scott LJ
    Drugs; 2009 Jun; 69(9):1229-37. PubMed ID: 19537839
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Linaclotide: a novel compound for the treatment of irritable bowel syndrome with constipation.
    Rothstein RD; Friedenberg FK
    Expert Opin Pharmacother; 2013 Oct; 14(15):2125-32. PubMed ID: 24007408
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lubiprostone (Amitiza) for irritable bowel syndrome with constipation.
    Med Lett Drugs Ther; 2008 Jul; 50(1290):53-4. PubMed ID: 18617872
    [No Abstract]   [Full Text] [Related]  

  • 24. Efficacy and safety of oral lubiprostone in constipated patients with or without irritable bowel syndrome: a randomized, placebo-controlled and dose-finding study.
    Fukudo S; Hongo M; Kaneko H; Ueno R
    Neurogastroenterol Motil; 2011 Jun; 23(6):544-e205. PubMed ID: 21303430
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome--results of two randomized, placebo-controlled studies.
    Drossman DA; Chey WD; Johanson JF; Fass R; Scott C; Panas R; Ueno R
    Aliment Pharmacol Ther; 2009 Feb; 29(3):329-41. PubMed ID: 19006537
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lubiprostone: a new drug for the treatment of chronic idiopathic constipation.
    Baker DE
    Rev Gastroenterol Disord; 2007; 7(4):214-22. PubMed ID: 18192957
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current and emerging treatments for irritable bowel syndrome with constipation and chronic idiopathic constipation: focus on prosecretory agents.
    Thomas RH; Luthin DR
    Pharmacotherapy; 2015 Jun; 35(6):613-30. PubMed ID: 26016701
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacologic treatment of constipation: what is new?
    Pohl D; Tutuian R; Fried M
    Curr Opin Pharmacol; 2008 Dec; 8(6):724-8. PubMed ID: 18687411
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Food and Drug Administration approves lubiprostone for irritable bowel syndrome with constipation.
    Lang L
    Gastroenterology; 2008 Jul; 135(1):7. PubMed ID: 18541153
    [No Abstract]   [Full Text] [Related]  

  • 30. A critical appraisal of lubiprostone in the treatment of chronic constipation in the elderly.
    Gras-Miralles B; Cremonini F
    Clin Interv Aging; 2013; 8():191-200. PubMed ID: 23439964
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetic and pharmacodynamic considerations for the current chronic constipation treatments.
    Müller-Lissner S
    Expert Opin Drug Metab Toxicol; 2013 Apr; 9(4):391-401. PubMed ID: 23425050
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lubiprostone.
    Winpenny JP
    IDrugs; 2005 May; 8(5):416-22. PubMed ID: 15883925
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term safety and effectiveness of lubiprostone, a chloride channel (ClC-2) activator, in patients with chronic idiopathic constipation.
    Lembo AJ; Johanson JF; Parkman HP; Rao SS; Miner PB; Ueno R
    Dig Dis Sci; 2011 Sep; 56(9):2639-45. PubMed ID: 21769655
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of lubiprostone in patients with chronic constipation.
    Barish CF; Drossman D; Johanson JF; Ueno R
    Dig Dis Sci; 2010 Apr; 55(4):1090-7. PubMed ID: 20012484
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of the chloride channel activator lubiprostone for constipation in adults with cystic fibrosis: a case series.
    O'Brien CE; Anderson PJ; Stowe CD
    Ann Pharmacother; 2010 Mar; 44(3):577-81. PubMed ID: 20179256
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of harm in the pharmacotherapy of irritable bowel syndrome.
    Shah E; Kim S; Chong K; Lembo A; Pimentel M
    Am J Med; 2012 Apr; 125(4):381-93. PubMed ID: 22444104
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lubiprostone: a chloride channel activator.
    Lacy BE; Levy LC
    J Clin Gastroenterol; 2007 Apr; 41(4):345-51. PubMed ID: 17413599
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lubiprostone for constipation in adults with cystic fibrosis: a pilot study.
    O'Brien CE; Anderson PJ; Stowe CD
    Ann Pharmacother; 2011 Sep; 45(9):1061-6. PubMed ID: 21852592
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [New therapeutical approaches for treatment of irritable bowel syndrome].
    Siegert F; Nieber K
    Med Monatsschr Pharm; 2010 Aug; 33(8):285-92; quiz 293-4. PubMed ID: 21189648
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New treatment targets for the management of irritable bowel syndrome.
    Rao S; Weber HC
    Curr Opin Endocrinol Diabetes Obes; 2014 Feb; 21(1):9-14. PubMed ID: 24300740
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.